Identification of a novel compound that suppresses breast cancer invasiveness by inhibiting transforming growth factor-β signaling via estrogen receptor α

Journal of Cancer

Volumn 5, Issue 5, 2014, Pages 336-343

  Goto, Natsuka ^a   Hiyoshi, Hiromi ^a   Ito, Ichiaki ^a   Iida, Keisuke ^b   Nakajima, Yuka ^a   Nagasawa, Kazuo ^b   Yanagisawa, Junn ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Breast cancer; Compounds; ER ; Invasion and metastasis; TGF

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA; N 23; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN PS2; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR INVASION;

EID: 84897015734     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7202     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. doi:10.3322/caac.20107.
2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell. 1995; 83: 835-9.
3. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002; 108: 465-74.
4. Curtis Hewitt S, Couse JF, Korach KS. Estrogen receptor transcription and transactivation: Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res. 2000; 2: 345-52.
5. Warner M, Nilsson S, Gustafsson JA. The estrogen receptor family. Curr Opin Obstet Gynecol. 1999; 11: 249-54.
6. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002; 296: 1642-4. doi:10.1126/science.1071884.
7. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev. 1999; 20: 321-44.
8. Elliston JF, Fawell SE, Klein-Hitpass L, Tsai SY, Tsai MJ, Parker MG, et al. Mechanism of estrogen receptor-dependent transcription in a cell-free system. Mol Cell Biol. 1990; 10: 6607-12.
9. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Sem in Oncol. 2001; 28: 291-304.
10. Morris C, Wakeling A. Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer. 2002; 9: 267-76.
11. Sporn MB, Roberts AB. TGF-beta: problems and prospects. Cell Regul. 1990; 1: 875-82.
12. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem. 1997; 272: 27678-85.
13. Liu X, Sun Y, Constantinescu SN, Karam E, Weinberg RA, Lodish HF. Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci USA. 1997; 94: 10669-74.
14. Wharton K, Derynck R. TGFbeta family signaling: novel insights in development and disease. Development. 2009; 136: 3691-7. doi:10.1242/dev.040584.
15. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010; 70: 5649-69. doi:10.1158/0008-5472.CAN-10-1040.
16. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G, et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006; 66: 2202-9. doi:10.1158/0008-5472.CAN-05-3560.
17. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA. 2005; 102: 13909-14. doi:10.1073/pnas.0506517102.
18. Ito I, Hanyu A, Wayama M, Goto N, Katsuno Y, Kawasaki S, et al. Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation. J Biol Chem. 2010; 285: 14747-55. doi:10.1074/jbc. M109.093039.
19. Goto N, Hiyoshi H, Ito I, Tsuchiya M, Nakajima Y, Yanagisawa J. Estrogen and antiestrogens alter breast cancer invasiveness by modulating the transforming growth factor-beta signaling pathway. Cancer Sci. 2011; 102: 1501-8. doi:10.1111/j.1349-7006.2011.01977.x.
20. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985; 45: 584-90.
21. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000; 89: 817-25.
22. Murayama A, Ohmori K, Fujimura A, Minami H, Yasuzawa-Tanaka K, Kuroda T, et al. Epigenetic control of rDNA loci in response to intracellular energy status. Cell. 2008; 133: 627-39. doi:10.1016/j.cell.2008.03.030.
23. Kajiro M, Hirota R, Nakajima Y, Kawanowa K, So-ma K, Ito I, et al. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat Cell Biol. 2009; 11: 312-9. doi:10.1038/ncb1839.
24. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998; 17: 3091-100. doi:10.1093/emboj/17.11.3091.
25. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 1371-88.
26. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003; 3: 807-21. doi:10.1038/nrc1208.
27. Thompson EW, Reich R, Shima TB, Albini A, Graf J, Martin GR, et al. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 1988; 48: 6764-8.
28. Borley AC, Hiscox S, Gee J, Smith C, Shaw V, Barrett-Lee P, et al. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Res. 2008; 10: R103. doi:10.1186/bcr2206.
29. Paredes J, Stove C, Stove V, Milanezi F, Van Marck V, Derycke L, et al. P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res. 2004; 64: 8309-17. doi:10.1158/0008-5472.CAN-04-0795.